Skip to main content

HCC 23: Prostate, Breast, and Other Cancers and Tumors

HCC 23, Prostate, Breast, and Other Cancers and Tumors, is one of the 115 payment categories in the CMS-HCC V28 model. 234 ICD-10-CM codes map to it in the payment year 2027 mapping, and a documented diagnosis in the category adds a relative factor of 0.186 to the risk score of a community, non-dual, aged beneficiary (0.233 disabled, 0.197 institutional). It is overridden when a more severe category in its hierarchy is present (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, HCC 22). In its hierarchy, HCC 22 overrides it when both are coded, at a community aged factor of 0.363 (+0.177).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ICD-10-CM to HCC mapping: PY2027 initial ICD-10-CM mappings (dates of service 2026) (payment year 2027); CMS-HCC V28 model software: CMS-HCC V28 software V2826.115.T2 (PY2027 initial) (payment year 2027). Next CMS release: PY2028 advance notice (February 2027) and the PY2027 midyear final mapping (spring 2027).

Mapped ICD-10-CM codes
234
Factor, community non-dual aged
0.186
Factor, institutional
0.197
Hierarchy
Overridden by HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, HCC 22

Relative factors by segment

Each segment is a separate regression; the factor is added to the beneficiary's demographic factors and other categories, then normalized and reduced by the coding intensity adjustment before it meets the plan's base rate. A factor of 1.000 equals the expected cost of an average beneficiary.

CMS-HCC V28 relative factors for HCC 23 by model segment
SegmentModel codeRelative factor
Community, non-dual, agedCNA_HCC230.186
Community, non-dual, disabledCND_HCC230.233
Community, full-benefit dual, agedCFA_HCC230.196
Community, full-benefit dual, disabledCFD_HCC230.218
Community, partial-benefit dual, agedCPA_HCC230.203
Community, partial-benefit dual, disabledCPD_HCC230.237
Long-term institutionalINS_HCC230.197

Hierarchy

Hierarchical condition categories pay only the most severe manifestation of a disease. When HCC 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) or HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid) or HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) or HCC 20 (Lung and Other Severe Cancers) or HCC 21 (Lymphoma and Other Cancers) or HCC 22 (Bladder, Colorectal, and Other Cancers) is also documented for the same beneficiary, HCC 23 is dropped from the score.

ICD-10-CM codes that map to HCC 23

234 codes map to this category in the PY2027 initial mapping, concentrated in the C50 (57), C69 (27), C43 (24), D03 (23), C76 (11), Q85 (11) code families. CMS built that mapping from codes valid in FY2025 and FY2026, and descriptions are the CMS mapping descriptions. None of these codes was deleted in the October 1, 2026 update.

ICD-10-CM codes mapped to HCC 23 in the CMS PY2027 initial mapping
ICD-10-CMDescription
C43.0Malignant melanoma of lip
C43.10Malignant melanoma of unspecified eyelid, including canthus
C43.111Malignant melanoma of right upper eyelid, including canthus
C43.112Malignant melanoma of right lower eyelid, including canthus
C43.121Malignant melanoma of left upper eyelid, including canthus
C43.122Malignant melanoma of left lower eyelid, including canthus
C43.20Malignant melanoma of unspecified ear and external auricular canal
C43.21Malignant melanoma of right ear and external auricular canal
C43.22Malignant melanoma of left ear and external auricular canal
C43.30Malignant melanoma of unspecified part of face
C43.31Malignant melanoma of nose
C43.39Malignant melanoma of other parts of face
C43.4Malignant melanoma of scalp and neck
C43.51Malignant melanoma of anal skin
C43.52Malignant melanoma of skin of breast
C43.59Malignant melanoma of other part of trunk
C43.60Malignant melanoma of unspecified upper limb, including shoulder
C43.61Malignant melanoma of right upper limb, including shoulder
C43.62Malignant melanoma of left upper limb, including shoulder
C43.70Malignant melanoma of unspecified lower limb, including hip
C43.71Malignant melanoma of right lower limb, including hip
C43.72Malignant melanoma of left lower limb, including hip
C43.8Malignant melanoma of overlapping sites of skin
C43.9Malignant melanoma of skin, unspecified
C47.4Malignant neoplasm of peripheral nerves of abdomen
C49.4Malignant neoplasm of connective and soft tissue of abdomen
C49.A0Gastrointestinal stromal tumor, unspecified site
C49.A1Gastrointestinal stromal tumor of esophagus
C49.A2Gastrointestinal stromal tumor of stomach
C49.A3Gastrointestinal stromal tumor of small intestine
C49.A4Gastrointestinal stromal tumor of large intestine
C49.A5Gastrointestinal stromal tumor of rectum
C49.A9Gastrointestinal stromal tumor of other sites
C50.011Malignant neoplasm of nipple and areola, right female breast
C50.012Malignant neoplasm of nipple and areola, left female breast
C50.019Malignant neoplasm of nipple and areola, unspecified female breast
C50.021Malignant neoplasm of nipple and areola, right male breast
C50.022Malignant neoplasm of nipple and areola, left male breast
C50.029Malignant neoplasm of nipple and areola, unspecified male breast
C50.111Malignant neoplasm of central portion of right female breast
C50.112Malignant neoplasm of central portion of left female breast
C50.119Malignant neoplasm of central portion of unspecified female breast
C50.121Malignant neoplasm of central portion of right male breast
C50.122Malignant neoplasm of central portion of left male breast
C50.129Malignant neoplasm of central portion of unspecified male breast
C50.211Malignant neoplasm of upper-inner quadrant of right female breast
C50.212Malignant neoplasm of upper-inner quadrant of left female breast
C50.219Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221Malignant neoplasm of upper-inner quadrant of right male breast
C50.222Malignant neoplasm of upper-inner quadrant of left male breast
C50.229Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311Malignant neoplasm of lower-inner quadrant of right female breast
C50.312Malignant neoplasm of lower-inner quadrant of left female breast
C50.319Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321Malignant neoplasm of lower-inner quadrant of right male breast
C50.322Malignant neoplasm of lower-inner quadrant of left male breast
C50.329Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411Malignant neoplasm of upper-outer quadrant of right female breast
C50.412Malignant neoplasm of upper-outer quadrant of left female breast
C50.419Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421Malignant neoplasm of upper-outer quadrant of right male breast
C50.422Malignant neoplasm of upper-outer quadrant of left male breast
C50.429Malignant neoplasm of upper-outer quadrant of unspecified male breast
C50.511Malignant neoplasm of lower-outer quadrant of right female breast
C50.512Malignant neoplasm of lower-outer quadrant of left female breast
C50.519Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521Malignant neoplasm of lower-outer quadrant of right male breast
C50.522Malignant neoplasm of lower-outer quadrant of left male breast
C50.529Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611Malignant neoplasm of axillary tail of right female breast
C50.612Malignant neoplasm of axillary tail of left female breast
C50.619Malignant neoplasm of axillary tail of unspecified female breast
C50.621Malignant neoplasm of axillary tail of right male breast
C50.622Malignant neoplasm of axillary tail of left male breast
C50.629Malignant neoplasm of axillary tail of unspecified male breast
C50.811Malignant neoplasm of overlapping sites of right female breast
C50.812Malignant neoplasm of overlapping sites of left female breast
C50.819Malignant neoplasm of overlapping sites of unspecified female breast
C50.821Malignant neoplasm of overlapping sites of right male breast
C50.822Malignant neoplasm of overlapping sites of left male breast
C50.829Malignant neoplasm of overlapping sites of unspecified male breast
C50.911Malignant neoplasm of unspecified site of right female breast
C50.912Malignant neoplasm of unspecified site of left female breast
C50.919Malignant neoplasm of unspecified site of unspecified female breast
C50.921Malignant neoplasm of unspecified site of right male breast
C50.922Malignant neoplasm of unspecified site of left male breast
C50.929Malignant neoplasm of unspecified site of unspecified male breast
C50.A0Malignant inflammatory neoplasm of unspecified breast
C50.A1Malignant inflammatory neoplasm of right breast
C50.A2Malignant inflammatory neoplasm of left breast
C54.0Malignant neoplasm of isthmus uteri
C54.1Malignant neoplasm of endometrium
C54.2Malignant neoplasm of myometrium
C54.3Malignant neoplasm of fundus uteri
C54.8Malignant neoplasm of overlapping sites of corpus uteri
C54.9Malignant neoplasm of corpus uteri, unspecified
C55Malignant neoplasm of uterus, part unspecified
C60.0Malignant neoplasm of prepuce
C60.1Malignant neoplasm of glans penis
C60.2Malignant neoplasm of body of penis
C60.8Malignant neoplasm of overlapping sites of penis
C60.9Malignant neoplasm of penis, unspecified
C61Malignant neoplasm of prostate
C62.00Malignant neoplasm of unspecified undescended testis
C62.01Malignant neoplasm of undescended right testis
C62.02Malignant neoplasm of undescended left testis
C62.10Malignant neoplasm of unspecified descended testis
C62.11Malignant neoplasm of descended right testis
C62.12Malignant neoplasm of descended left testis
C62.90Malignant neoplasm of unspecified testis, unspecified whether descended or undescended
C62.91Malignant neoplasm of right testis, unspecified whether descended or undescended
C62.92Malignant neoplasm of left testis, unspecified whether descended or undescended
C63.00Malignant neoplasm of unspecified epididymis
C63.01Malignant neoplasm of right epididymis
C63.02Malignant neoplasm of left epididymis
C63.10Malignant neoplasm of unspecified spermatic cord
C63.11Malignant neoplasm of right spermatic cord
C63.12Malignant neoplasm of left spermatic cord
C63.2Malignant neoplasm of scrotum
C63.7Malignant neoplasm of other specified male genital organs
C63.8Malignant neoplasm of overlapping sites of male genital organs
C63.9Malignant neoplasm of male genital organ, unspecified
C69.00Malignant neoplasm of unspecified conjunctiva
C69.01Malignant neoplasm of right conjunctiva
C69.02Malignant neoplasm of left conjunctiva
C69.10Malignant neoplasm of unspecified cornea
C69.11Malignant neoplasm of right cornea
C69.12Malignant neoplasm of left cornea
C69.20Malignant neoplasm of unspecified retina
C69.21Malignant neoplasm of right retina
C69.22Malignant neoplasm of left retina
C69.30Malignant neoplasm of unspecified choroid
C69.31Malignant neoplasm of right choroid
C69.32Malignant neoplasm of left choroid
C69.40Malignant neoplasm of unspecified ciliary body
C69.41Malignant neoplasm of right ciliary body
C69.42Malignant neoplasm of left ciliary body
C69.50Malignant neoplasm of unspecified lacrimal gland and duct
C69.51Malignant neoplasm of right lacrimal gland and duct
C69.52Malignant neoplasm of left lacrimal gland and duct
C69.60Malignant neoplasm of unspecified orbit
C69.61Malignant neoplasm of right orbit
C69.62Malignant neoplasm of left orbit
C69.80Malignant neoplasm of overlapping sites of unspecified eye and adnexa
C69.81Malignant neoplasm of overlapping sites of right eye and adnexa
C69.82Malignant neoplasm of overlapping sites of left eye and adnexa
C69.90Malignant neoplasm of unspecified site of unspecified eye
C69.91Malignant neoplasm of unspecified site of right eye
C69.92Malignant neoplasm of unspecified site of left eye
C73Malignant neoplasm of thyroid gland
C75.0Malignant neoplasm of parathyroid gland
C75.4Malignant neoplasm of carotid body
C75.5Malignant neoplasm of aortic body and other paraganglia
C75.8Malignant neoplasm with pluriglandular involvement, unspecified
C75.9Malignant neoplasm of endocrine gland, unspecified
C76.0Malignant neoplasm of head, face and neck
C76.1Malignant neoplasm of thorax
C76.2Malignant neoplasm of abdomen
C76.3Malignant neoplasm of pelvis
C76.40Malignant neoplasm of unspecified upper limb
C76.41Malignant neoplasm of right upper limb
C76.42Malignant neoplasm of left upper limb
C76.50Malignant neoplasm of unspecified lower limb
C76.51Malignant neoplasm of right lower limb
C76.52Malignant neoplasm of left lower limb
C76.8Malignant neoplasm of other specified ill-defined sites
C80.1Malignant (primary) neoplasm, unspecified
C80.2Malignant neoplasm associated with transplanted organ
D03.0Melanoma in situ of lip
D03.10Melanoma in situ of unspecified eyelid, including canthus
D03.111Melanoma in situ of right upper eyelid, including canthus
D03.112Melanoma in situ of right lower eyelid, including canthus
D03.121Melanoma in situ of left upper eyelid, including canthus
D03.122Melanoma in situ of left lower eyelid, including canthus
D03.20Melanoma in situ of unspecified ear and external auricular canal
D03.21Melanoma in situ of right ear and external auricular canal
D03.22Melanoma in situ of left ear and external auricular canal
D03.30Melanoma in situ of unspecified part of face
D03.39Melanoma in situ of other parts of face
D03.4Melanoma in situ of scalp and neck
D03.51Melanoma in situ of anal skin
D03.52Melanoma in situ of breast (skin) (soft tissue)
D03.59Melanoma in situ of other part of trunk
D03.60Melanoma in situ of unspecified upper limb, including shoulder
D03.61Melanoma in situ of right upper limb, including shoulder
D03.62Melanoma in situ of left upper limb, including shoulder
D03.70Melanoma in situ of unspecified lower limb, including hip
D03.71Melanoma in situ of right lower limb, including hip
D03.72Melanoma in situ of left lower limb, including hip
D03.8Melanoma in situ of other sites
D03.9Melanoma in situ, unspecified
D18.02Hemangioma of intracranial structures
D32.0Benign neoplasm of cerebral meninges
D32.1Benign neoplasm of spinal meninges
D32.9Benign neoplasm of meninges, unspecified
D33.0Benign neoplasm of brain, supratentorial
D33.1Benign neoplasm of brain, infratentorial
D33.2Benign neoplasm of brain, unspecified
D33.3Benign neoplasm of cranial nerves
D33.4Benign neoplasm of spinal cord
D33.7Benign neoplasm of other specified parts of central nervous system
D33.9Benign neoplasm of central nervous system, unspecified
D35.2Benign neoplasm of pituitary gland
D35.3Benign neoplasm of craniopharyngeal duct
D35.4Benign neoplasm of pineal gland
D42.0Neoplasm of uncertain behavior of cerebral meninges
D42.1Neoplasm of uncertain behavior of spinal meninges
D42.9Neoplasm of uncertain behavior of meninges, unspecified
D43.0Neoplasm of uncertain behavior of brain, supratentorial
D43.1Neoplasm of uncertain behavior of brain, infratentorial
D43.2Neoplasm of uncertain behavior of brain, unspecified
D43.3Neoplasm of uncertain behavior of cranial nerves
D43.4Neoplasm of uncertain behavior of spinal cord
D43.8Neoplasm of uncertain behavior of other specified parts of central nervous system
D43.9Neoplasm of uncertain behavior of central nervous system, unspecified
D44.3Neoplasm of uncertain behavior of pituitary gland
D44.4Neoplasm of uncertain behavior of craniopharyngeal duct
D44.5Neoplasm of uncertain behavior of pineal gland
D44.6Neoplasm of uncertain behavior of carotid body
D44.7Neoplasm of uncertain behavior of aortic body and other paraganglia
D45Polycythemia vera
D47.3Essential (hemorrhagic) thrombocythemia
D49.6Neoplasm of unspecified behavior of brain
Q85.00Neurofibromatosis, unspecified
Q85.01Neurofibromatosis, type 1
Q85.02Neurofibromatosis, type 2
Q85.03Schwannomatosis
Q85.09Other neurofibromatosis
Q85.1Tuberous sclerosis
Q85.81PTEN hamartoma tumor syndrome
Q85.82Other Cowden syndrome
Q85.83Von Hippel-Lindau syndrome
Q85.89Other phakomatoses, not elsewhere classified
Q85.9Phakomatosis, unspecified

What changed from V24

The payment year 2025 mapping carries both models for the same codes. Of the 231 codes it maps to V28 HCC 23, every one already paid under V24; the largest source is V24 HCC 12 (Breast, Prostate, and Other Cancers and Tumors) with 220 codes. The V28 community, non-dual, aged factor is 0.186 against 0.150 for V24 HCC 12.

V24 categories that the HCC 23 codes belonged to (PY2025 mapping)
V24 HCCV24 categoryCodes now in HCC 23V24 codes with no V28 HCCV24 factor (CNA)
12Breast, Prostate, and Other Cancers and Tumors2200 of 2710.150
10Lymphoma and Other Cancers90 of 5950.675
48Coagulation Defects and Other Specified Hematological Disorders239 of 720.192

V24 and V28 number their categories independently, so the same diagnosis usually carries a different HCC number in each model. The V24 to V28 crosswalk report lists every category pair, and the glossary explains the 2020 CMS-HCC V24 model and the V28 model that replaced it.

Inpatient groups where these diagnoses land

Appendix B of the v44 MS-DRG Definitions Manual places the codes in this category in the logic of 63 MS-DRGs. The groups with the most shared codes are below; a hospital stay coded with one of these diagnoses groups there when it is the principal diagnosis, or when the DRG's logic uses it as a qualifying secondary diagnosis.

MS-DRGs whose logic lists the most HCC 23 codes
MS-DRGTitleShared codes
DRG 582Mastectomy for Malignancy with CC/MCC57
DRG 583Mastectomy for Malignancy without CC/MCC57
DRG 597Malignant Breast Disorders with MCC57
DRG 598Malignant Breast Disorders with CC57
DRG 599Malignant Breast Disorders without CC/MCC57
DRG 124Other Disorders of the Eye with MCC or Thrombolytic Agent37
DRG 125Other Disorders of the Eye without MCC37
DRG 595Major Skin Disorders with MCC37
DRG 596Major Skin Disorders without MCC37
DRG 054Nervous System Neoplasms with MCC27

Local coverage policies that list these diagnoses

Medicare Administrative Contractors name covered ICD-10-CM codes in the billing and coding articles attached to their LCDs. These policies share the most codes with HCC 23 in the current Medicare Coverage Database export (one policy per topic; overlap counts after each). For the services these policies govern, the same diagnoses are covered indications, so the documentation that supports the category also supports the claim for the service.

Where these codes sat in the V22 model

The V28 recalibration renumbered and regrouped categories; this table shows which legacy V22 categories the same ICD-10 codes belonged to, which is the quickest way to reconcile a V22-era HCC gap list with the current model.

V22 categories that the HCC 23 codes mapped to
V22 HCCCodes
12223
109
482

Part D: the RxHCC categories of these codes

The same diagnoses feed the RxHCC model, which adjusts Medicare Part D payments. Of the 234 codes in HCC 23, 221 also map to a prescription drug category and 13 carry none; the categories are below, and the RxHCC hub has their 2027 MA-PD, PDP and PACE factors.

RxHCC V08 categories that the HCC 23 codes map to
RxHCCCategoryCodes
RxHCC 22Prostate, Breast, Bladder, and Other Cancers and Tumors210
RxHCC 20Lung, Kidney, and Other Cancers; Secondary Cancer of Lymph Nodes and Other Sites9
RxHCC 21Lymphomas and Other Hematologic Cancers2

Capturing and defending the category

A category counts for a payment year when a mapped diagnosis is documented at least once during the data collection year by an acceptable provider type at a face-to-face or audio-video encounter, and when the note shows the condition was monitored, evaluated, assessed or treated. Chronic conditions do not carry forward: a category that is not re-documented in the year drops out of the score, which is why annual wellness visits and problem-list reconciliation are where most recapture happens. Risk adjustment data validation audits sample enrollees and ask for the medical record behind each submitted category; an unsupported category is removed and, under the extrapolation rules, the error rate is applied across the contract. The QuickIntell risk adjustment product surfaces suspected and unsupported categories from the chart, and the HCC hub lists every V28 category with its factor and code count.

For teams evaluating QuickIntell software

Evaluate risk adjustment review software

For teams reviewing documentation across a cohort, explore source evidence, proposed findings, reviewer decisions and audit handoffs. Confirm the program, payment year and model scope during evaluation. A category lookup is not a patient-specific coding or payment determination.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

Which ICD-10 codes map to HCC 23?

234 ICD-10-CM codes map to HCC 23 in the CMS PY2027 initial mapping, for example C43.0 Malignant melanoma of lip; C43.10 Malignant melanoma of unspecified eyelid, including canthus; C43.111 Malignant melanoma of right upper eyelid, including canthus; C43.112 Malignant melanoma of right lower eyelid, including canthus. The full list is on this page; a code counts only when it is documented at a face-to-face or video encounter in the data collection year and supported by the record.

How much does HCC 23 add to a risk score?

The V28 relative factor for HCC 23 is 0.186 for a community, non-dual, aged beneficiary, 0.196 for full-benefit dual aged, 0.233 for non-dual disabled and 0.197 for long-term institutional members. A factor of 1.000 equals the expected annual cost of an average beneficiary, so the category's share of the payment follows the plan's base rate for that segment.

Does HCC 23 count together with related categories?

No. Within a hierarchy only the most severe category is paid. HCC 23 is dropped when HCC 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) or HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid) or HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers) or HCC 20 (Lung and Other Severe Cancers) or HCC 21 (Lymphoma and Other Cancers) or HCC 22 (Bladder, Colorectal, and Other Cancers) is also present.

What has to be documented for HCC 23 to be valid?

One of the 234 mapped codes (such as C43.0) must be recorded by an acceptable provider type during a face-to-face or audio-video encounter in the service year, with the note showing that the condition (Prostate, Breast, and Other Cancers and Tumors) was monitored, evaluated, assessed or treated. Risk adjustment data validation audits recover payment for categories the record does not support, so the code on the claim and the assessment in the note must match.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Relative factors and mappings are reproduced from the CMS risk adjustment model files as an operational reference. Payment depends on the plan's base rate, normalization, the coding intensity adjustment and the enrollee's segment. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.